Neramexane

From Self-sufficiency
Jump to: navigation, search
Neramexane
130px
Systematic (IUPAC) name
1,3,3,5,5-pentamethylcyclohexanamine
Identifiers
CAS Number 219810-59-0
ATC code none
PubChem CID 6433106
Chemical data
Formula C11H23N
Molar mass 169.307 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Neramexane is a drug related to memantine,[1] which acts as an NMDA antagonist[2] and has neuroprotective effects.[3] It is being developed for various possible applications, including treatment of tinnitus[4][5], Alzheimer's disease,[6] drug addiction[7] and as an analgesic.[8] Animal studies have also suggested antidepressant[9] and nootropic[10] actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist.[11]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. Jump up Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG. A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization. Journal of Neural Transmission. 2007;114(12):1529-37. PMID 17728997
  2. Jump up Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Current Pharmaceutical Design. 2002;8(10):835-43. PMID 11945134
  3. Jump up Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotoxicity Research. 2002 Mar;4(2):119-26. PMID 12829411
  4. Jump up ClinicalTrials.gov NCT00405886 Neramexane for Tinnitus
  5. Jump up ClinicalTrials.gov NCT00739635 Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
  6. Jump up Rammes G, Schierloh A. Neramexane (merz pharmaceuticals/forest laboratories). IDrugs. 2006 Feb;9(2):128-35. PMID 16523403
  7. Jump up Kotlinska J, Biala G, Rafalski P, Bochenski M, Danysz W. Effect of neramexane on ethanol dependence and reinforcement. European Journal of Pharmacology. 2004 Oct 25;503(1-3):95-8. PMID 15496302
  8. Jump up Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. European Journal of Pain. 2008 Jan;12(1):17-29. PMID: 17449306
  9. Jump up Kos T, Legutko B, Danysz W, Samoriski G, Popik P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1128-36. PMID 16740621
  10. Jump up Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacology, Biochemistry and Behaviour. 2006 Oct;85(2):298-306. Epub 2006 Oct 11. PMID: 17045636
  11. Jump up Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.